公开(公告)号：US20220145406A1

公开(公告)日：2022-05-12

申请号：US17416988

申请日：2019-12-19

Applicant: ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITÉ DE MONTPELLIER

Inventor： Philippe POULETTY ,  Hartmut EHRLICH ,  Didier SCHERRER ,  Jamal TAZI ,  Laurent MANCHON

IPC: C12Q1/70 ,  A61K31/706 ,  C12N15/113

Abstract: Biomarkers and uses thereof in monitoring, assessing, and/or treatment of viral infections, or inflammatory diseases, disorders, or conditions, or cancer.

公开(公告)号：US20200172525A1

公开(公告)日：2020-06-04

申请号：US16787471

申请日：2020-02-11

Applicant: ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

Inventor： Jamal TAZI ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Didier SCHERRER ,  Julien SANTO

IPC: C07D413/04 ,  C07D215/38 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12 ,  C07D217/02 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/42 ,  C07D215/46

Abstract: The present disclosure is generally directed to the manufacture and use of compounds described herein for preventing, inhibiting or treating cancer, AIDS and/or premature aging, or the manufacture and use of a pharmaceutical composition comprising at least one of the compounds, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for preventing, inhibiting or treating cancer, AIDS and/or premature aging.

公开(公告)号：US20190328747A1

公开(公告)日：2019-10-31

申请号：US16333531

申请日：2017-09-14

Applicant: ABIVAX

Inventor： Sandrine CRABE ,  Didier SCHERRER ,  Hartmut EHRLICH ,  Philippe POULETTY

IPC: A61K31/553 ,  A61K39/39 ,  A61P35/00 ,  A61P31/00 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28

Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.

公开(公告)号：US20180030078A1

公开(公告)日：2018-02-01

申请号：US15552587

申请日：2016-02-19

Applicant: ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

Inventor： Didier SCHERRER ,  Aude GARCEL ,  Noelie CAMPOS ,  Jamal TAZI ,  Audrey VAUTRIN ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Pauline FORNARELLI

IPC: C07H17/02

CPC classification number: C07H17/02 ,  C07D405/12

Abstract: The present invention relates to a quinoline derivative of formula (1) or one of its pharmaceutically acceptable salts. The present invention further relates to said quinoline derivative for medicament and for use in the treatment or prevention of a viral or retroviral infection and in particular AIDS or an AIDS-related condition or Human Immunodeficiency virus (HIV). The present invention also relates to a pharmaceutical composition comprising said quinoline derivative and to the process for preparing it as to a novel intermediate compound.

公开(公告)号：US20170204063A1

公开(公告)日：2017-07-20

申请号：US15326755

申请日：2015-07-17

Applicant: ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

Inventor： Jamal TAZI ,  Romain NAJMAN ,  Florence MAHUTEAU ,  Didier SCHERRER ,  Karim CHEBLI ,  Michael HAHNE

IPC: C07D215/38 ,  C07D401/12

CPC classification number: C07D215/38 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/5377 ,  C07D401/12 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/5023 ,  G01N33/5055

Abstract: The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R″ does not exist when Q is O; R′ independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxy! group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a —O—P(=O)—(OR3XOR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among: (IIa), (IIIa) or anyone of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of an inflammatory disease.

公开(公告)号：US20170197938A1

公开(公告)日：2017-07-13

申请号：US15326698

申请日：2015-07-17

Applicant: ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

Inventor： Jamal TAZI ,  Romain NAJMAN ,  Florence MAHUTEAU ,  Didier SCHERRER ,  Aude GARCEL ,  Noëlie CAMPOS

IPC: C07D401/12

CPC classification number: C07D401/12

Abstract: The present invention relates to a compound of formula (1) in the form of a base or addition salt with an acid, particularly a pharmaceutically acceptable acid. It further relates to a pharmaceutical composition including the compound and at least one pharmaceutically acceptable excipient, to a process for preparing said compound and to a corresponding intermediate compound.

公开(公告)号：US20150307478A1

公开(公告)日：2015-10-29

申请号：US14789250

申请日：2015-07-01

Applicant: ABIVAX ,  CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE MONTPELLIER 2

Inventor： Jamal TAZI ,  Florence MAHUTEAU ,  Romain NAJMAN ,  Didier SCHERRER ,  Noelie CAMPOS ,  Aude GARCEL

IPC: C07D403/12 ,  C07D215/38 ,  C07D241/44 ,  C07D401/12

CPC classification number: C07D403/12 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D241/44 ,  C07D401/12

Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NR1R2 group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a phenoxy group, or a (C1-C4)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, or a (C1-C4)alkoxy group, R″ is a hydrogen atom or a (C1-C4)alkyl group, n is 1, 2, or 3, and n′ is 1 or 2.

Abstract translation: 具有下式的化合物或其药学上可接受的盐：其中：R独立地表示氢原子，卤素原子，（C1-C3）烷基，-NR1R2基，（C1-C3）氟烷氧基， -NO 2基，苯氧基或（C1-C4）烷氧基，R1和R2独立地为氢原子或（C1-C3）烷基，R'为氢原子，卤素原子，（C1 -C 3）烷基或（C 1 -C 4）烷氧基，R“为氢原子或（C 1 -C 4）烷基，n为1,2或3，n'为1或2。

公开(公告)号：US20240343716A1

公开(公告)日：2024-10-17

申请号：US18435619

申请日：2024-02-07

Applicant: ABIVAX ,  CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

Inventor： Jamal TAZI ,  Florence MAHUTEAU ,  Pierre ROUX ,  Romain NAJMAN ,  Didier SCHERRER ,  Carsten BROCK ,  Nathalie CAHUZAC ,  Gilles GADEA ,  Noelie CAMPOS ,  Aude GARCEL ,  Julien SANTO

IPC: C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

CPC classification number: C07D413/04 ,  A61K31/4709 ,  A61K31/4985 ,  C07D213/74 ,  C07D215/38 ,  C07D215/42 ,  C07D215/46 ,  C07D217/02 ,  C07D241/44 ,  C07D401/12 ,  C07D403/12

Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being:




where:



R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group;
R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and
R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.

公开(公告)号：US20240308964A1

公开(公告)日：2024-09-19

申请号：US18660578

申请日：2024-05-10

Applicant: ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

Inventor： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC: C07D215/38 ,  A61P31/14 ,  C07D401/12 ,  C07D405/12

CPC classification number: C07D215/38 ,  A61P31/14 ,  C07D401/12 ,  C07D405/12

Abstract: A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification




wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(═O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

公开(公告)号：US20230142547A1

公开(公告)日：2023-05-11

申请号：US17913063

申请日：2021-03-19

Applicant: ABIVAX

Inventor： Jamal TAZI ,  Hartmut EHRLICH ,  Philippe POULETTY ,  Julien SANTO ,  Didier SCHERRER

IPC: A61K31/47 ,  A61K9/00 ,  A61K31/7064

CPC classification number: A61K31/47 ,  A61K9/0019 ,  A61K9/007 ,  A61K31/7064

Abstract: The treatment or prevention of a Coronaviridae infection, and conditions related thereto; in particular a Coronaviridae infection in humans. In particular, the compounds, pharmaceutical compositions and medicaments for treating and/or preventing a Coronaviridae infection and/or its long-term consequences. The uses and methods for assessing a Coronaviridae infection or the efficacy of a treatment of such infections.